Plasmodium vivax
Plasmodium vivax is a protozoal parasite and a human pathogen. This parasite is the most frequent and widely distributed cause of recurring malaria. Although it is less virulent than "Plasmodium falciparum", the deadliest of the five human malaria parasites, "P. vivax" malaria infections can lead to severe disease and death, often due to splenomegaly (a pathologically enlarged spleen). "P. vivax" is carried by the female "Anopheles" mosquito; the males do not bite. Health. Epidemiology. "Plasmodium vivax" is found mainly in Asia, Latin America, and in some parts of Africa. "P. vivax" is believed to have originated in Asia , but recent studies have shown that wild chimpanzees and gorillas throughout central Africa are endemically infected with parasites that are closely related to human "P. vivax." These findings indicate that human P. vivax is of African origin. "Plasmodium vivax" accounts for 65% of malaria cases in Asia and South America. Unlike "Plasmodium falciparum", "Plasmodium vivax" is capable of undergoing sporogonic development in the mosquito at lower temperatures. It has been estimated that 2.5 billion people are at risk of infection with this organism. Although the Americas contribute 22% of the global area at risk, high endemic areas are generally sparsely  populated and the region contributes only 6% to the total population at risk. In Africa, the widespread lack of the Duffy antigen in the population has ensured that stable transmission is constrained to Madagascar and parts of the Horn of Africa. It contributes 3.5% of global population at risk. Central Asia is responsible for 82% of global population at risk with high endemic areas coinciding with dense populations particularly in India and Myanmar. South East Asia has areas of high endemicity in Indonesia and Papua New Guinea and overall contributes 9% of global population at risk. P. vivax is carried  by at least 71 mosquito species. Many vivax vectors thrive in temperate climates—as far north as Finland. Some prefer to bite outdoors or during the daytime, hampering the effectiveness of indoor insecticide and bed nets. Several key vector species have yet to be grown in the lab for closer study, and insecticide resistance is unquantified. Clinical presentation. Pathogenesis results from rupture of infected red blood cells, leading to fever. Infected red blood cells may also stick to each other and to walls of capillaries. Vessels plug up and deprive tissues of oxygen. Infection may also cause the spleen to  enlarge. Unlike "P. falciparum", "P. vivax" can populate the bloodstream, even before a patient shows symptoms, with sexual-stage parasites—the form ingested by mosquitoes prior to biting the next victim. Consequently, prompt treatment of symptomatic patients does not necessarily help stop an outbreak, as it does with falciparum malaria, in which fevers occur as sexual stages develop. Even when symptoms appear, because the disease is usually not immediately fatal, the parasite continues to multiply. "Plasmodium vivax" can cause a more unusual form of malaria with atypical symptoms. It has been known to debut with hiccups, loss of taste, lack  of fever, pain while swallowing, cough and urinary discomfort. The parasite can lie dormant in the liver for days to years, causing no symptoms and remaining undetectable in blood tests. They form hypnozoites, a small stage that nestles inside an individual liver cell. This name derives from “sleeping organisms”. The hypnozoites allow the parasite to survive in more temperate zones, where mosquitoes bite only part of the year. A single infectious bite can trigger six or more relapses a year, leaving sufferers more vulnerable to other diseases. Other infectious diseases, including falciparum malaria, appear to trigger relapses. Serious complications. Serious  complications for malaria are dormant liver stage parasites, organ failures such as acute kidney failure. More complications of malaria can also be impairment of consciousness, neurological abnormalities, hypoglycemia and low blood pressures caused by cardiovascular collapse, clinical jaundice and or other vital organ dysfunctions and coagulation defects. The most serious complication ultimately being death. Prevention. The main way to prevent malaria is through vector control. There are mostly three main forms that the vector can be controlled: (1) insecticide-treated mosquito nets, (2) indoor residual spraying and (3) antimalarial drugs. Long-lasting insecticidal nets (LLNs) are the preferred method of  control because it is the most cost effective. The WHO is currently strategizing how to ensure that the net is properly maintained to protect people at risk. The second option is indoor residual spraying and has been proven effective if at least 80% of the homes are sprayed. However, such method is only effective for 3-6months. A drawback to these two methods, unfortunately, is that mosquito resistance against these insecticides has risen. National malaria control efforts are undergoing rapid changes to ensure the people are given the most effective method of vector control. Lastly, antimalarial drugs can also be  used to prevent infection from developing into a clinical disease. However, there has also been an increase resistance to antimalarial medicine. In 2015 the World Health Organization (WHO) drew up a plan to address vivax malaria, as part of their Global Technical Strategy for Malaria. Diagnosis. "P. vivax" and "P. ovale" that has been sitting in EDTA for more than 30 minutes before the blood film is made will look very similar in appearance to "P. malariae",["source needed"] which is an important reason to warn the laboratory immediately when the blood sample is drawn so they can process the sample  as soon as it arrives. Blood films are preferably made within 30 minutes of the blood draw and must certainly be made within an hour of the blood being drawn. Diagnosis can be done with the strip fast test of antibodies. Treatment. Chloroquine remains the treatment of choice for "vivax" malaria, except in Indonesia's Irian Jaya (Western New Guinea) region and the geographically contiguous Papua New Guinea, where chloroquine resistance is common (up to 20% resistance). Chloroquine resistance is an increasing problem in other parts of the world, such as Korea and India. When chloroquine resistance is common or  when chloroquine is contraindicated, then artesunate is the drug of choice, except in the U.S., where it is not approved for use. Where an artemisinin-based combination therapy has been adopted as the first-line treatment for "P. falciparum" malaria, it may also be used for P. vivax malaria in combination with primaquine for radical cure. An exception is artesunate plus sulfadoxine-pyrimethamine (AS+SP), which is not effective against P. vivax in many places. Mefloquine is a good alternative and in some countries is more readily available. Atovaquone-proguanil is an effective alternative in patients unable to tolerate chloroquine. Quinine  may be used to treat "vivax" malaria but is associated with inferior outcomes. 32–100% of patients will relapse following successful treatment of "P. vivax" infection if a radical cure (eradication of liver stages) is not given. Eradication of the liver stages is achieved by giving primaquine. Patients with glucose-6-phosphate dehydrogenase deficiency risk haemolysis. G6PD is an enzyme important for blood chemistry. No field-ready test is available. Recently, this point has taken particular importance for the increased incidence of vivax malaria among travelers. At least a 14-day course of primaquine is required for the radical treatment of "P.  vivax". Tafenoquine. In 2013 a Phase IIb trial was completed that studied a single-dose alternative drug named tafenoquine. It is an 8-aminoquinoline, of the same family as primaquine, developed by researchers at the Walter Reed Army Institute of Research in the 1970s and tested in safety trials. It languished, however, until the push for malaria elimination sparked new interest in primaquine alternatives. Among patients who received a 600-mg dose, 91% were relapse-free after 6 months. Among patients who received primaquine, 24% relapsed within 6 months. "The data are absolutely spectacular," Wells says. Ideally, he says, researchers  will be able to combine the safety data from the Army's earlier trials with the new study in a submission to the U.S. Food and Drug Administration for approval. Like primaquine, tafenoquine causes hemolysis in people who are G6PD deficient. In 2013 researchers produced cultured human "microlivers" that supported liver stages of both "P. falciparum" and "P. vivax" and may have also created hypnozoites. Eradication. Mass-treating populations with a primaquine can kill the hypnozoites, exempting those with G6PD deficiency. However, the standard regimen requires a daily pill for 14 days across an asymptomatic population. Korea. "P. vivax" is  the only indigenous malaria parasite on the Korean peninsula. In the years following the Korean War (1950–53), malaria-eradication campaigns successfully reduced the number of new cases of the disease in North Korea and South Korea. In 1979, World Health Organization declared the Korean peninsula vivax malaria-free, but the disease unexpectedly re-emerged in the late 1990s and still persists today. Several factors contributed to the re-emergence of the disease, including reduced emphasis on malaria control after 1979, floods and famine in North Korea, emergence of drug resistance and possibly global warming. Most cases are identified along the  Korean Demilitarized Zone. As such, vivax malaria offers the two Koreas an opportunity to work together on an important health problem that affects both countries. Drug Targets. Given that drugs that target the various life stages of the parasite can sometimes have undesirable side effects, it is desirable to come up with drug molecules targeting specific proteins/enzymes that are essential for the parasite's survival or that can compromise the fitness of the organism. Enzymes in the Purine salvage pathway had been favorite targets to this end. However, given the high degree of conservation in purine metabolism across the  parasite and its host, there could be potential cross-reactivity making it difficult to design selective drugs against the parasite. To overcome this, recent efforts have focused on deducing the function of orphan hypothetical proteins whose functions have been unknown. Though, a lot of the hypothetical proteins have role in secondary metabolism, targeting them will be beneficial from two perspectives, i.e., specificity and reducing the virulence of the pathogen with no or minimal undesirable cross-reactivities. Biology. Life cycle. Like all malaria parasites, "P. vivax" has a complex life cycle. It infects a definitive insect host, where sexual reproduction occurs , and an intermediate vertebrate host, where asexual amplification occurs. In "P. vivax", the definitive hosts are Anopheles mosquitoes (also known as the vector), while humans are the intermediate asexual hosts. During its life cycle, "P. vivax" assumes many different physical forms. Asexual forms: Sexual forms: Human infection. "P. vivax" human infection occurs when an infected mosquito feeds on a human. During feeding, the mosquito injects saliva to prevent blood clotting (along with sporozoites), thousands of sporozoites are inoculated into human blood; within a half-hour the sporozoites reach the liver. There they enter hepatic cells, transform into the trophozoite form  and feed on hepatic cells, and reproduce asexually. This process gives rise to thousands of merozoites (plasmodium daughter cells) in the circulatory system and the liver. The incubation period of human infection usually ranges from ten to seventeen days and sometimes up to a year. Persistent liver stages allow relapse up to five years after elimination of red blood cell stages and clinical cure. Liver stage. The "P. vivax" sporozoite enters a hepatocyte and begins its exoerythrocytic schizogony stage. This is characterized by multiple rounds of nuclear division without cellular segmentation. After a certain number of nuclear divisions, the parasite  cell will segment and merozoites are formed. There are situations where some of the sporozoites do not immediately start to grow and divide after entering the hepatocyte, but remain in a dormant, hypnozoite stage for weeks or months. The duration of latency is thought to be variable from one hypnozoite to another and the factors that will eventually trigger growth are not known; this might explain how a single infection can be responsible for a series of waves of parasitaemia or "relapses". It has been assumed that different strains of "P. vivax" have their own characteristic relapse pattern and timing . However, such recurrent parasitaemia is probably being over-attributed to hypnozoite activation. Two newly recognized, non-hypnozoite, probable contributing sources to recurrent peripheral "P. vivax" parasitaemia are erythrocytic forms in bone marrow and the spleen. Erythrocytic cycle. "P. vivax" preferentially penetrates young red blood cells (reticulocytes), unlike "Plasmodium falciparum" which can invade erythrocytes. In order to achieve this, merozoites have two proteins at their apical pole (PvRBP-1 and PvRBP-2). The parasite uses the Duffy blood group antigens (Fy6) to penetrate red blood cells. This antigen does not occur in the majority of humans in West Africa [phenotype Fy (a-b- )]. As a result, "P. vivax" occurs less frequently in West Africa. The parasitised red blood cell is up to twice as large as a normal red cell and Schüffner's dots (also known as Schüffner's stippling or Schüffner's granules) are seen on the infected cell's surface. Schüffner's dots have a spotted appearance, varying in color from light pink, to red, to red-yellow, as coloured with Romanovsky stains. The parasite within it is often wildly irregular in shape (described as "amoeboid"). Schizonts of "P. vivax" have up to twenty merozoites within them. It is rare to  see cells with more than one parasite within them. Merozoites will only attach to immature blood cell (reticulocytes) and therefore it is unusual to see more than 3% of all circulating erythrocytes parasitised. Mosquito stage. Parasite life cycle in mosquitoes includes all stages of sexual reproduction: Mosquito Infection and Gamete Formation. When a female Anopheles mosquito bites an infected person, gametocytes and other stages of the parasite are transferred to the mosquito stomach. Gametocytes ultimately develop into gametes, a process known as gametogony. Microgametocytes become very active, and their nuclei undergo fission (i.e. amitosis) to each give 6-8 daughter  nuclei, which becomes arranged at the periphery. The cytoplasm develops long thin flagella like projections, then a nucleus enter into each one of these extensions. These cytoplasmic extensions later break off as mature male gametes (microgametes). This process of formation of flagella-like microgametes or male gametes is known as exflagellation. Macrogametocytes show very little change. They develop a cone of reception at one side and becomes mature as macrogametocytes (female gametes). Fertilization. Male gametes move actively in the stomach of mosquitoes in search of female gametes. Male gametes then enter into female gametes through the cone of reception. The  complete fusion of 2 gametes results in the formation of zygote. Here, fusion of 2 dissimilar gametes occurs, known as anisogamy. The zygote remains inactive for sometime but it soon elongates, becomes vermiform (worm-like) and motile. It is now known as ookinete. The pointed ends of ookinete penetrate the stomach wall and come to lie below its outer epithelial layer. Here the zygote becomes spherical and develops a cyst wall around itself. The cyst wall is derived partly from the stomach tissues and partly produced by the zygote itself. At this stage, the zygote is known as an oocyst . The oocyst absorbs nourishment and grows in size. Oocysts protrude from the surface of stomach, giving it a blistered appearance. In a highly infected mosquito, as many as 1000 oocysts may be seen. Sporogony. The oocyst nucleus divides repeatedly to form large number of daughter nuclei. At the same time, the cytoplasm develops large vacuoles and forms numerous cytoplasmic masses. These cytoplasmic masses then elongate and a daughter nuclei migrates into each mass. The resulting sickle-shaped bodies are known as sporozoites. This phase of asexual multiplication is known as sporogony and is completed in about 10–21 days. The oocyst  then bursts and sporozoites are released into the body cavity of mosquito. Sporozoites eventually reach the salivary glands of mosquito via its hemolymph. The mosquito now becomes infectious. Salivary glands of a single infected mosquito may contain as many as 200,000 sporozoites. When the mosquito bites a healthy person, thousands of sporozoites are infected into the blood along with the saliva and the cycle starts again. Taxonomy. "P. vivax" can be divided into two clades one that appears to have origins in the Old World and a second that originated in the New World. The distinction can be made on  the basis of the structure of the A and S forms of the rRNA. A rearrangement of these genes appears to have occurred in the New World strains. It appears that a gene conversion occurred in an Old World strain and this strain gave rise to the New World strains. The timing of this event has yet to be established. At present both types of "P. vivax" circulate in the Americas. The monkey parasite - "Plasmodium simium" - is related to the Old World strains rather than to the New World strains. A specific name - "Plasmodium collinsi" - has been proposed for the  New World strains but this suggestion has not been accepted to date. Miscellaneous. It has been suggested that P. vivax has horizontally acquired genetic material from humans. Plasmodium vivax is not known to have a particular gram stain (negative vs. positive) and may appear as either. There is evidence that P. vivax is itself infected by viruses. Therapeutic use. "P. vivax" was used between 1917 and the 1940s for malariotherapy, that is, to create very high fevers to combat certain diseases such as tertiary syphilis. In 1917, the inventor of this technique, Julius Wagner-Jauregg, received the Nobel Prize in  Physiology or Medicine for his discoveries. However, the technique was dangerous, killing about 15% of patients, so it is no longer in use.